IMA
ImageneBio, Inc.6.25
+0.08+1.3%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
69.89MP/E (TTM)
-Basic EPS (TTM)
-4.77Dividend Yield
0%Recent Filings
10-K
FY2025 results
ImageneBio posted FY2025 results for the year ended December 31, 2025, as an emerging growth clinical-stage biopharma post its July 2025 merger with Legacy Inmagene, featuring no revenue and ongoing R&D losses typical for the sector. Lacking quarterly breakdowns or financial statements in the filing, specific Q4 metrics remain undisclosed. The Phase 2b trial for lead asset IMG-007 in atopic dermatitis advanced with a protocol amendment for optimized dosing and site expansion; topline data awaits 2027. Cash position undisclosed, yet funding needs loom large. Board adopted director compensation policy December 2025. We identified a material weakness in internal controls. Dependency on IMG-007 success alone imperils quarterly momentum.
8-K
Q4 results, $135M cash
ImageneBio reported Q4 and full-year 2025 results, ending with $135.3M in cash after a $75M private placement tied to its Ikena merger. IMG-007's Phase 2b ADAPTIVE trial advances on track for 2027 topline data, showing clean safety—no pyrexia, malignancies, or serious infections across 150+ subjects. New CMO Ben Porter-Brown joined. Cash funds the program.
8-K
CMO resigns, no disputes
8-K
IMG-007 Phase 2b update
ImageneBio updated its corporate presentation on November 19, 2025, highlighting IMG-007, a differentiated anti-OX40 antibody in Phase 2b for atopic dermatitis with topline data expected in 2027. Phase 1b/2a showed 87% mean EASI reduction at week 20 and durable responses; proof-of-concept also emerged in alopecia areata. Cash runway extends through 2027. Risks include clinical delays.
FBLG
FibroBiologics, Inc.
0.24-0.02
IMAB
I-MAB
4.63-0.01
IMMX
Immix Biopharma, Inc.
5.94-0.27
IMNM
Immunome, Inc.
23.48+0.84
IMRX
Immuneering Corporation
5.74-0.04
IMTX
Immatics N.V.
10.09+0.11
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
TRML
Tourmaline Bio, Inc.
47.98+47.98
ZBIO
Zenas BioPharma, Inc.
36.89+4.30
ZURA
Zura Bio Limited
4.12+0.05